Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) ~~An anticancer or an anti-metastatic agent for gene therapy containing~~ A pharmaceutical composition for treating a solid tumor, or metastasis thereof, said composition comprising a gene carrier or cells harboring a gene encoding a recombinant protein consisting of human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) ~~gene~~ as an effective ingredient.

2. (Currently amended) The ~~agent~~ composition according to claim 1, wherein the LK68 gene comprises a nucleotide sequence represented by SEQ. ID. No. 1.

3. (Currently amended) The ~~agent~~ composition according to claim 1, wherein the gene carrier harboring the LK68 gene is a vector or a recombinant virus.

4. (Currently amended) The ~~agent~~ composition according to claim 3, wherein the vector is selected from ~~a group consisting of~~ a linear DNA vector, a plasmid DNA vector and a recombinant viral vector.

5. (Currently amended) The ~~agent~~ composition according to claim 3, wherein the recombinant virus is selected from ~~a group consisting of~~ retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.

6. (Currently amended) The ~~agent~~ composition according to claim 1, wherein the cells are selected from ~~a group consisting of~~ hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells.

7. (Currently amended) The ~~agent~~ composition according to claim 1, wherein the gene carrier is selected from ~~a group consisting of~~ pSecTag-LK68, pLXSN-LK68, rAAV-LK68 and pAAV-LK68.

8. (Currently amended) The ~~agent~~ composition according to claim 1, wherein the LK8 gene comprises a nucleotide sequence represented by SEQ. ID. No. 2.

9. (Currently amended) The ~~agent~~ composition according to claim 1, wherein the gene carrier harboring the LK8 gene is a vector or a recombinant virus.

10. (Currently amended) The ~~agent~~ composition according to claim 9, wherein the vector is selected from ~~a group consisting of~~ a linear DNA vector, a plasmid DNA vector and a recombinant viral vector.

11. (Currently amended) The ~~agent~~ composition according to claim 9, wherein the recombinant virus is selected from ~~a group consisting of~~ retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.

12. (Currently amended) The ~~agent~~ composition according to claim 9, wherein the gene carrier is selected from ~~a group consisting of~~ pSecTag-LK8, pLXSN-LK8, rAAV-LK8 and pAAV-LK8.

13. (Currently amended) The ~~agent~~ composition according to claim 3, wherein the vector is included by 0.05 ~ 500 mg.

14. (Currently amended) The ~~agent~~ composition according to claim 3, wherein the recombinant virus is included by 10^3 - 10^{12} IU.

15. (Currently amended) The ~~agent~~ composition according to claim 1, wherein the cells are included by 10^3 - 10^8 e.a.

16. (Currently amended) The ~~agent~~ composition according to claim 1, wherein the ~~cancer~~ solid tumor is selected from ~~a group consisting of~~ colon carcinoma, liver cancer, lung cancer, breast cancer, brain tumor, prostatic carcinoma, skin cancer, stomach cancer, pancreas cancer, lymphoma, kidney cancer, ovarian cancer and metastatic tumor.

17. (Currently amended) The ~~agent~~ composition according to claim 16, wherein the ~~cancer~~ solid tumor is selected from ~~a group consisting of~~ colon carcinoma, liver cancer, lymphoma ~~or~~ and metastatic tumor.

18. (Currently amended) A method for ~~the~~ prevention or ~~the~~ treatment of a solid tumor, which includes a step of parenteral administration of the ~~agent for gene therapy~~ composition of claim 1 to an individual.

19. (Currently amended) The method according to claim 18, wherein the prevention or the treatment of a solid tumor is accomplished by ~~the~~ inhibition of ~~the~~ growth and ~~the~~ metastasis of the solid tumor.

20. (Currently amended) The method according to claim 18, wherein the administration of a gene carrier harboring human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) gene is accomplished by a method selected from ~~a group consisting of~~ chemical method, physical method, conjugation using liposome, a method using receptor and virus~~, etc~~.

21. (Currently amended) The method according to claim 18, wherein the administration is characterized by injecting cells selected from ~~a group consisting of~~ hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells transfected with human apolipoprotein(a) kringle KIV9-KIV10-KV(LK68) or KV(LK8) gene to a patient.

22. (Currently amended) The ~~agent~~ composition according to claim 9, wherein the vector is included by 0.05 ~ 500 mg.

23. (Currently amended) The ~~agent~~ composition according to claim 9, wherein the recombinant virus is included by 10^3 - 10^{12} IU.